QPPV.COM KNOWLEDGE ASSESSMENT

Potential Serious Risk to Public Health: How It Is Assessed

Test your understanding of the concepts covered by Potential Serious Risk to Public Health: How It Is Assessed.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best describes the role of benefit-risk assessment in an Article 29 concern?

A major therapeutic benefit automatically cancels any credible serious risk Benefit-risk is irrelevant once a safety concern is identified The concern should be considered in light of benefits, alternatives, exposure and whether the risk can be adequately managed Only the frequency of the risk matters

Question 2 of 10 Which situation most appropriately supports invoking the Article 29 mechanism during an MRP or DCP?

The CMS disagrees with the RMS wording preference but accepts the overall regulatory conclusion The CMS cannot approve the relevant regulatory position because it considers that doing so could create a potential serious risk to public health and provides detailed reasons The applicant has not answered every question by the preferred deadline The RMS requests additional information on a minor administrative issue

Question 3 of 10 Several spontaneous reports describe a rare, catastrophic event with a distinctive clinical pattern, strong biological plausibility and little evidence of alternative causes. What is the most appropriate regulatory interpretation?

The reports must be ignored because spontaneous reports cannot support regulatory assessment The reports automatically prove causality without further assessment The pattern may provide important evidence of a credible concern, although the totality of evidence and limitations must still be assessed The concern can only be considered if the event is common in the general population

Question 4 of 10 Which record would best support inspection-ready traceability of an Article 29 concern?

Only the final regulatory decision Only the applicant's preferred scientific interpretation The original objection, evidence reviewed, limitations, analyses, responses, coordination records, proposed measures and final outcome A numerical internal score with no supporting rationale

Question 5 of 10 Why should conflicting evidence be explicitly acknowledged in the regulatory record?

Because contradictory evidence automatically prevents any Article 29 concern Because authorities need to understand how evidence was weighted and why alternative interpretations were accepted or rejected Because only negative studies are legally relevant Because acknowledging conflict replaces the need for a conclusion

Question 6 of 10 What is CMDh's principal role after a qualifying MRP/DCP disagreement has been raised?

To determine automatically that the CMS is correct To provide a forum for Member States to examine the disagreement and seek agreement To replace the applicant's benefit-risk assessment To establish causality for every reported adverse event

Question 7 of 10 Which sequence best reflects a defensible assessment of a potential serious risk to public health?

Legal conclusion, preferred regulatory action, evidence selection, public-health assessment Observation, scientific assessment, potential clinical consequence, public-health significance, regulatory qualification Number of reports, seriousness classification, automatic referral, benefit assessment Applicant position, final decision, retrospective justification, evidence review

Question 8 of 10 What should a strong applicant response to an Article 29 concern primarily provide?

A general assertion that the RMS assessment is adequate Only a list of additional documents submitted A reasoned analysis of evidence, limitations, alternatives, clinical consequences, population relevance, benefit-risk and proposed measures A request to disregard contradictory evidence

Question 9 of 10 Which factor would most directly weaken an alleged product-related risk association?

A consistent temporal pattern and biological plausibility A high expected exposure after authorisation A strong alternative explanation from the underlying disease and a similar background incidence A clinically catastrophic possible outcome

Question 10 of 10 A company proposes a contraindication to address a credible serious risk. What should the assessment do next?

Assume the contraindication eliminates the concern Reject the proposal because risk minimisation can never address an Article 29 concern Evaluate whether the contraindication can reliably identify and protect the relevant population and what residual risk remains Treat the proposal as proof that the initial concern was invalid

Potential Serious Risk to Public Health: How It Is Assessed

Cookie Settings